Want to snare the next CSL dividend? Read this

Despite achieving the top end of its guidance for the 2022 financial year, the CSL Limited (ASX: CSL) share price has remained flat since the release of the results.

At last week’s market close, shares in the biotherapeutics giant finished at $295.99. This compares to the $296.40 they were trading at before reporting the company’s FY 2022 scorecard.

CSL CEO and managing director Paul Perreault acknowledged the resilient performance against the ongoing challenges of COVID-19, saying it was a ‘good result’.

Nonetheless, the board opted to maintain its final dividend of US$1.18 (AU$1.68) per share. Due to favourable currency movements, this translates to a lift of 9 cents or 5.6% over the prior corresponding period.

Investors were quick to react to the results, sending CSL shares to a monthly low of $278.89. But as the day went on, the share price mostly recovered to end at $292.50 – down 1.32%.

Let’s look at the details you need to know about the upcoming dividend.

Time is running out for the CSL dividend

Investors will have until the end of today to secure the CSL dividend.

The ex-dividend date falls on Tuesday 6 September.

This means if you buy the company’s shares before market close today and hold them until tomorrow morning, you’ll be eligible for the final dividend.

The dividend is also franked at 10% which equates to US 11.8 cents (AU 18 cents) per share.

Keep in mind though, when a company’s shares trade ex-dividend, the share price tends to fall in proportion to the dividend paid out. However, this can vary depending on how the market is tracking for the day, as well as investor sentiment.

If you do manage to scoop up some CSL shares, a dividend payment of roughly AU$1.68 per share will land in your bank account on 5 October.

The details of the exact payment currency equivalent will be released on 9 September.

How has the CSL share price performed in 2022?

At the start of 2022, the CSL share price nosedived 17% to hit a 52-week low of $240.10 in mid-February.

However, the share quickly rebounded and traded around $270 for several months.

When the new financial year kicked off, CSL shares rose and have been hovering under the $300 mark.

For the calendar year, the biotech’s share price is up 2%.

In comparison, the S&P/ASX 200 Health Care (ASX: XHJ) sector is down 5% over the same period.

CSL commands a market capitalisation of approximately $142.58 billion and has a dividend yield of 1.02%.

The post Want to snare the next CSL dividend? Read this appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 ASX 200 shares turning ex-dividend tomorrow
• Why is the CSL share price outperforming the ASX 200 on Friday?
• ASX 200 shares declared $42b of dividends in August. Here’s how you can get a slice
• How do CSL shares stack up against Cochlear following earnings season?
• Top ASX shares to buy in September 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Y39Px4n